Author Archive: BIOtechNOW Editor

The Journey from the Bench to Bedside

shutterstock_2103563

A partnership between a leading academic research center and a biologics company is aiming to develop new therapeutic opportunities Translational research enables therapies get to where they need to be – to the patient. The process is characterized by collaborative activity between university and company scientists. One recent example is the announcement of a three-year collaboration between MedImmune, the global biologics research and development arm of AstraZeneca, and the Clinical and Translational Science Institute (CTSI) Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Expand Investment in Basic Research Needed to Advance Medical Progress

Michael Coburn

In 2007, the Napier and Lane families struggled to find answers to their daughters’ developmental problems, which included impaired communication and socialization skills. Both of the girls had a disorder so rare that it subsequently became identified only by the name of the small fragment of chromosome 16 that was missing, namely “16p11.2 deletion syndrome.” Dan Pinkel and Joe Gray, researchers at the University of California, San Francisco developed microarray comparative genomic hybridization, a technology Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

From Participant to Judge in the International BioGENEius Challenge

Sagar

My name is Sagar Rambhia, and I participated in the 2011 International BioGENEius Challenge. Three years later, I have come back to be a judge at the 2014 International BioGENEius Challenge. I am 19 years old, and since competing in the 2011 BioGENEius Challenge, I have started my own company and continued to conduct biomedical engineering research. Back in 2011, as part of the BioGENEius Challenge, I was given the life-changing opportunity to present my Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

New Type of Prospective Survey Initiative

scientist-eyedropper

Our industry is on the cutting-edge of science aimed at developing new therapies for devastating and life-threatening diseases. To help advance innovation and promote the development of the next generation of treatments and cures, we must acknowledge that the scientific method does not operate in a vacuum. Robust, interactive FDA-Sponsor communication is a key element of modern drug development. However, in order to improve the drug development enterprise and the FDA review process further, the Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Delivering the Right Dose, Less Often

medical_research

Biologics are a growing area of drug development, including life-threatening and life-changing disorders such as cancer and rheumatoid arthritis. However, many biologics have short half-lives, and need to be dosed daily. To make them more convenient to use, as well as safer and more effective, researchers are developing delivery systems that keep the biologics in the body for longer, reducing the frequency of dosing. Swedish company Affibody is using the natural affinity of a naturally-occurring Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,